Unilife Medical Solutions ("Unilife") will continue to announce its results in Australian (A$) currency until the completion of a proposed redomiciliation of the Company to the U.S., and a proposed listing on NASDAQ. At present, U.S.$1.00 equals approximately A$1.17. The Full Preliminary Final Results for the Company (Appendix 4E) are available on the Financial Reports section of the Unilife website (www.unilife.com).

Earnings Result

Group Revenue for Unilife increased by 869% from A$4,170,166 (2008) to A$40,413,706 (2009). The increase in revenue was primarily due to payments received from the pharmaceutical partner. The Net Profit after tax for the year ended 30 June 2009 was A$12,806,494 representing a 249% increase in the Net Profit as compared with the previous corresponding year. The Directors do not recommend that a dividend relating to the year ended 30 June 2009 be paid. As such, there is no applicable record date.

Cash Flow

During the year ended 30 June 2009, the net cash provided by operating activities was A$8,961,562 (2008) net cash out flow (A$7,980,916). An amount of A$246,666 was invested in research and development (2008: A$562,929) and A$3,572,645 was invested in plant, property and equipment (2008: A$895,433).

Agreements with Major Pharmaceutical Partner

On July 1, 2008, Unilife entered into a Global Agreement with its major pharmaceutical partner (pharmaceutical partner) under which the partner paid Unilife a non-refundable fee of A$16.4 million (EUR 10 million) for the exclusive right to negotiate for the purchase of the Unilife Ready-to-Fill Syringe. On June 30, 2009, Unilife signed an Industrialization Agreement with its pharmaceutical partner for the Unilife Ready-to-Fill Syringe under which its partner committed to complete the funding of the A$30.4 million (EUR 17 million) industrialization program.

Combined with the A$16.4 million (EUR 10 million) non-refundable Exclusivity Fee paid to Unilife in 2008, this commitment to fund the industrialization program will represent a total expenditure by the pharmaceutical partner of approximately A$47 million between July 2008 and the end of 2010. Between now and the end of 2009, both parties will negotiate therapeutic drug class areas where the pharmaceutical partner would have the exclusive right to use the Unilife Ready-to-Fill Syringe. Under the Industrialization Agreement, Unilife has also retained the right to enter into agreements with other pharmaceutical companies that may seek to use the Unilife Ready-to-Fill Syringe with injectable drug products marketed in other therapeutic drug classes.

Industrialization Program for the Unilife Ready-to-Fill Syringe

The Industrialization Program for the Unilife Ready-to-Fill Syringe commenced on July 1, 2008. The original project plan targeted the scheduled completion of the Industrialization Program in the fourth quarter of 2011.